Apichope Pharmaceutical Group (300723.SZ) Subsidiary Receives Approval Notice for Oseltamivir Phosphate Capsules Drug Supplement Application

Stock News09-19

Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd. ("Apichope Pharmaceutical"), recently received the "Drug Supplement Application Approval Notice" for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. Following review, the application met the relevant requirements for drug registration, and approval was granted to add the 45mg specification with the issuance of a drug approval number.

The following related supplement application items were also approved: 1) Changes to excipient amounts in the formulation; 2) Changes to packaging materials and containers; 3) Registration standard modifications. The revised production process and quality standards shall be implemented as attached, with a validity period of 12 months. The package insert and labeling shall be revised accordingly, while other aspects shall follow the originally approved information.

The company's newly obtained approval notice for the Oseltamivir Phosphate Capsules drug supplement application signifies that the company now has the qualification to market this specification of the drug in the domestic market. This will further enrich the company's product pipeline and product categories, having a positive impact on the company's sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154748835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 11:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154748835","market":"fut","top_or_hot":-1,"title":"Apichope Pharmaceutical Group (300723.SZ) Subsidiary Receives Approval Notice for Oseltamivir Phosphate Capsules Drug Supplement Application","media":"Stock News","content":"<p>Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd. (\"Apichope Pharmaceutical\"), recently received the \"Drug Supplement Application Approval Notice\" for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. Following review, the application met the relevant requirements for drug registration, and approval was granted to add the 45mg specification with the issuance of a drug approval number.</p>\n<p>The following related supplement application items were also approved: 1) Changes to excipient amounts in the formulation; 2) Changes to packaging materials and containers; 3) Registration standard modifications. The revised production process and quality standards shall be implemented as attached, with a validity period of 12 months. The package insert and labeling shall be revised accordingly, while other aspects shall follow the originally approved information.</p>\n<p>The company's newly obtained approval notice for the Oseltamivir Phosphate Capsules drug supplement application signifies that the company now has the qualification to market this specification of the drug in the domestic market. This will further enrich the company's product pipeline and product categories, having a positive impact on the company's sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apichope Pharmaceutical Group (300723.SZ) Subsidiary Receives Approval Notice for Oseltamivir Phosphate Capsules Drug Supplement Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApichope Pharmaceutical Group (300723.SZ) Subsidiary Receives Approval Notice for Oseltamivir Phosphate Capsules Drug Supplement Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-19 11:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd. (\"Apichope Pharmaceutical\"), recently received the \"Drug Supplement Application Approval Notice\" for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. Following review, the application met the relevant requirements for drug registration, and approval was granted to add the 45mg specification with the issuance of a drug approval number.</p>\n<p>The following related supplement application items were also approved: 1) Changes to excipient amounts in the formulation; 2) Changes to packaging materials and containers; 3) Registration standard modifications. The revised production process and quality standards shall be implemented as attached, with a validity period of 12 months. The package insert and labeling shall be revised accordingly, while other aspects shall follow the originally approved information.</p>\n<p>The company's newly obtained approval notice for the Oseltamivir Phosphate Capsules drug supplement application signifies that the company now has the qualification to market this specification of the drug in the domestic market. This will further enrich the company's product pipeline and product categories, having a positive impact on the company's sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1154748835","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154748835","pubTimestamp":1758254059,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd. (\"Apichope Pharmaceutical\"), recently received the \"Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300723":"一品红","BK0239":"医药制造"},"translate_title":"阿匹乔普药业集团（300723.SZ）子公司获磷酸奥司他韦胶囊药品补充申请批准通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300723":1},"content_text":"Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd. (\"Apichope Pharmaceutical\"), recently received the \"Drug Supplement Application Approval Notice\" for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. Following review, the application met the relevant requirements for drug registration, and approval was granted to add the 45mg specification with the issuance of a drug approval number.\nThe following related supplement application items were also approved: 1) Changes to excipient amounts in the formulation; 2) Changes to packaging materials and containers; 3) Registration standard modifications. The revised production process and quality standards shall be implemented as attached, with a validity period of 12 months. The package insert and labeling shall be revised accordingly, while other aspects shall follow the originally approved information.\nThe company's newly obtained approval notice for the Oseltamivir Phosphate Capsules drug supplement application signifies that the company now has the qualification to market this specification of the drug in the domestic market. This will further enrich the company's product pipeline and product categories, having a positive impact on the company's sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154748835","isCrawlerRequest":true}